Panc 02.13
Panc 02.13
规格:
货期:
编号:TS211131
品牌:Testobio
| 产品名称： | Panc 02.13 |
|---|---|
| 商品货号： | TS211131 |
| Organism： | Homo sapiens, human |
| Tissue： | pancreas |
| Cell Type： | Epithelial |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | adenocarcinoma |
| Age： | 64 years |
| Gender： | female |
| Ethnicity： | White |
| Derivation： | Panc 02.13 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. |
| Clinical Data： | female
64 years
White |
| Antigen Expression： | MHC class I +; MHC class II - Blood type A; Rh+ |
| Oncogene： | K-ras + (wild-type)
Ref  Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Genes Expressed： | cytokeratins 7 and 18 |
| Cellular Products： | cytokeratins 7 and 18 |
| Tumorigenic： | Yes |
| Effects： | Yes, forms tumors in nude or SCID mice |
| Comments： | The cells have a reported plating efficiency of 100%. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subculture Ratio: 1:3 to 1:4 Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994
|
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 12 D13S317: 8,11 D16S539: 9,12 D5S818: 12 D7S820: 7,11 THO1: 6,9.3 TPOX: 8 vWA: 16,18 |
| Population Doubling Time： | 33.9 hrs |
| Name of Depositor： | EM Jaffee |
| Deposited As： | human |
| Year of Origin： | 1995 |
| References： | Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
Panc 02.13
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Panc 02.13 |
|---|---|
| 商品货号： | TS211131 |
| Organism： | Homo sapiens, human |
| Tissue： | pancreas |
| Cell Type： | Epithelial |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | adenocarcinoma |
| Age： | 64 years |
| Gender： | female |
| Ethnicity： | White |
| Derivation： | Panc 02.13 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. |
| Clinical Data： | female
64 years
White |
| Antigen Expression： | MHC class I +; MHC class II - Blood type A; Rh+ |
| Oncogene： | K-ras + (wild-type)
RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Genes Expressed： | cytokeratins 7 and 18 |
| Cellular Products： | cytokeratins 7 and 18 |
| Tumorigenic： | Yes |
| Effects： | Yes, forms tumors in nude or SCID mice |
| Comments： | The cells have a reported plating efficiency of 100%. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subculture Ratio: 1:3 to 1:4 Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994
|
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 12 D13S317: 8,11 D16S539: 9,12 D5S818: 12 D7S820: 7,11 THO1: 6,9.3 TPOX: 8 vWA: 16,18 |
| Population Doubling Time： | 33.9 hrs |
| Name of Depositor： | EM Jaffee |
| Deposited As： | human |
| Year of Origin： | 1995 |
| References： | Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
